Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Plasma Neurofilament Light and Alzheimer's Disease Biomarkers in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI).

Rafii MS, Donohue MC, Matthews DC, Muranevici G, Ness S, O'Bryant SE, Rissman RA.

J Alzheimers Dis. 2019 May 27. doi: 10.3233/JAD-190322. [Epub ahead of print]

PMID:
31156181
2.

Continuous Popliteal-Sciatic Blocks for Postoperative Analgesia: Traditional Proximal Catheter Insertion Superficial to the Paraneural Sheath Versus a New Distal Insertion Site Deep to the Paraneural Sheath.

Sztain JF, Finneran JJ 4th, Monahan AM, Khatibi B, Nguyen PL, Madison SJ, Bellars RH, Gabriel RA, Ahmed SS, Schwartz AK, Kent WT, Donohue MC, Padwal JA, Ilfeld BM.

Anesth Analg. 2019 Jun;128(6):e104-e108. doi: 10.1213/ANE.0000000000003693.

PMID:
31094804
3.

A randomized clinical trial to evaluate home-based assessment of people over 75 years old.

Sano M, Zhu CW, Kaye J, Mundt JC, Hayes TL, Ferris S, Thomas RG, Sun CK, Jiang Y, Donohue MC, Schneider LS, Egelko S, Aisen PS, Feldman HH; Alzheimer Disease Cooperative Study Investigators.

Alzheimers Dement. 2019 May;15(5):615-624. doi: 10.1016/j.jalz.2019.01.007. Epub 2019 Mar 11.

PMID:
30872114
4.

Nonlinear Distributional Mapping (NoDiM) for harmonization across amyloid-PET radiotracers.

Properzi MJ, Buckley RF, Chhatwal JP, Donohue MC, Lois C, Mormino EC, Johnson KA, Sperling RA, Schultz AP.

Neuroimage. 2019 Feb 1;186:446-454. doi: 10.1016/j.neuroimage.2018.11.019. Epub 2018 Nov 17.

PMID:
30458305
5.

Bayesian latent time joint mixed-effects model of progression in the Alzheimer's Disease Neuroimaging Initiative.

Li D, Iddi S, Thompson WK, Rafii MS, Aisen PS, Donohue MC.

Alzheimers Dement (Amst). 2018 Aug 29;10:657-668. doi: 10.1016/j.dadm.2018.07.008. eCollection 2018.

6.

Participant satisfaction with dementia prevention research: Results from Home-Based Assessment trial.

Sano M, Egelko S, Zhu CW, Li C, Donohue MC, Ferris S, Kaye J, Mundt JC, Sun CK, Aisen PS, Feldman HH.

Alzheimers Dement. 2018 Nov;14(11):1397-1405. doi: 10.1016/j.jalz.2018.05.016. Epub 2018 Oct 5.

PMID:
30297140
7.

Defining the Optimal Target Population for Trials of Polyunsaturated Fatty Acid Supplementation Using the Erythrocyte Omega-3 Index: A Step Towards Personalized Prevention of Cognitive Decline?

Coley N, Raman R, Donohue MC, Aisen PS, Vellas B, Andrieu S.

J Nutr Health Aging. 2018;22(8):982-998. doi: /10.1007/s12603-018-1052-2.

PMID:
30272103
8.

Continuous Popliteal-Sciatic Blocks for Postoperative Analgesia: Traditional Proximal Catheter Insertion Superficial to the Paraneural Sheath Versus a New Distal Insertion Site Deep to the Paraneural Sheath.

Sztain JF, Finneran JJ 4th, Monahan AM, Khatibi B, Nguyen PL, Madison SJ, Bellars RH, Gabriel RA, Ahmed SS, Schwartz AK, Kent WT, Donohue MC, Padwal JA, Ilfeld BM.

Anesth Analg. 2018 Aug 9. doi: 10.1213/ANE.0000000000003693. [Epub ahead of print]

PMID:
30096081
9.

Estimating the Evolution of Disease in the Parkinson's Progression Markers Initiative.

Iddi S, Li D, Aisen PS, Rafii MS, Litvan I, Thompson WK, Donohue MC.

Neurodegener Dis. 2018;18(4):173-190. doi: 10.1159/000488780. Epub 2018 Aug 8.

10.

Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts.

Buckley RF, Mormino EC, Amariglio RE, Properzi MJ, Rabin JS, Lim YY, Papp KV, Jacobs HIL, Burnham S, Hanseeuw BJ, Doré V, Dobson A, Masters CL, Waller M, Rowe CC, Maruff P, Donohue MC, Rentz DM, Kirn D, Hedden T, Chhatwal J, Schultz AP, Johnson KA, Villemagne VL, Sperling RA; Alzheimer's Disease Neuroimaging Initiative; Australian Imaging, Biomarker and Lifestyle study of ageing; Harvard Aging Brain Study.

Alzheimers Dement. 2018 Sep;14(9):1193-1203. doi: 10.1016/j.jalz.2018.04.010. Epub 2018 May 24.

PMID:
29803541
11.

Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials.

Iwatsubo T, Iwata A, Suzuki K, Ihara R, Arai H, Ishii K, Senda M, Ito K, Ikeuchi T, Kuwano R, Matsuda H; Japanese Alzheimer's Disease Neuroimaging Initiative, Sun CK, Beckett LA, Petersen RC, Weiner MW, Aisen PS, Donohue MC; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2018 Aug;14(8):1077-1087. doi: 10.1016/j.jalz.2018.03.009. Epub 2018 May 9.

12.

Proximal Versus Distal Continuous Adductor Canal Blocks: Does Varying Perineural Catheter Location Influence Analgesia? A Randomized, Subject-Masked, Controlled Clinical Trial.

Sztain JF, Khatibi B, Monahan AM, Said ET, Abramson WB, Gabriel RA, Finneran JJ 4th, Bellars RH, Nguyen PL, Ball ST, Gonzales FB, Ahmed SS, Donohue MC, Padwal JA, Ilfeld BM.

Anesth Analg. 2018 Jul;127(1):240-246. doi: 10.1213/ANE.0000000000003422.

PMID:
29750695
13.

Disease progression models for dominantly-inherited Alzheimer's disease.

Li D, Donohue MC.

Brain. 2018 May 1;141(5):1244-1246. doi: 10.1093/brain/awy089. No abstract available.

14.

Bayesian latent time joint mixed effect models for multicohort longitudinal data.

Li D, Iddi S, Thompson WK, Donohue MC; Alzheimer’s Disease Neuroimaging Initiative.

Stat Methods Med Res. 2019 Mar;28(3):835-845. doi: 10.1177/0962280217737566. Epub 2017 Nov 23.

PMID:
29168432
15.

Elevated Brain Amyloid in Cognitively Normal Individuals-Reply.

Donohue MC, Aisen PS.

JAMA. 2017 Oct 10;318(14):1393-1394. doi: 10.1001/jama.2017.12962. No abstract available.

PMID:
29049582
16.

Cross-validation of optimized composites for preclinical Alzheimer's disease.

Donohue MC, Sun CK, Raman R, Insel PS, Aisen PS; AN-ADNI; AIBL; J-ADNI.

Alzheimers Dement (N Y). 2017 Jan;3(1):123-129. doi: 10.1016/j.trci.2016.12.001.

17.

Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons.

Donohue MC, Sperling RA, Petersen R, Sun CK, Weiner MW, Aisen PS; Alzheimer’s Disease Neuroimaging Initiative.

JAMA. 2017 Jun 13;317(22):2305-2316. doi: 10.1001/jama.2017.6669.

18.
19.

Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β.

Mormino EC, Papp KV, Rentz DM, Donohue MC, Amariglio R, Quiroz YT, Chhatwal J, Marshall GA, Donovan N, Jackson J, Gatchel JR, Hanseeuw BJ, Schultz AP, Aisen PS, Johnson KA, Sperling RA.

Alzheimers Dement. 2017 Sep;13(9):1004-1012. doi: 10.1016/j.jalz.2017.01.018. Epub 2017 Feb 28.

20.

Cognitive and functional changes associated with Aβ pathology and the progression to mild cognitive impairment.

Insel PS, Donohue MC, Mackin RS, Aisen PS, Hansson O, Weiner MW, Mattsson N; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2016 Dec;48:172-181. doi: 10.1016/j.neurobiolaging.2016.08.017. Epub 2016 Aug 26.

PMID:
27710807
21.

Infection Rates of Electrical Leads Used for Percutaneous Neurostimulation of the Peripheral Nervous System.

Ilfeld BM, Gabriel RA, Saulino MF, Chae J, Peckham PH, Grant SA, Gilmore CA, Donohue MC, deBock MG, Wongsarnpigoon A, Boggs JW.

Pain Pract. 2017 Jul;17(6):753-762. doi: 10.1111/papr.12523. Epub 2016 Nov 11. Review.

22.

Using social and mobile tools for weight loss in overweight and obese young adults (Project SMART): a 2 year, parallel-group, randomised, controlled trial.

Godino JG, Merchant G, Norman GJ, Donohue MC, Marshall SJ, Fowler JH, Calfas KJ, Huang JS, Rock CL, Griswold WG, Gupta A, Raab F, Fogg BJ, Robinson TN, Patrick K.

Lancet Diabetes Endocrinol. 2016 Sep;4(9):747-755. doi: 10.1016/S2213-8587(16)30105-X. Epub 2016 Jul 14.

23.

Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology.

Insel PS, Mattsson N, Mackin RS, Schöll M, Nosheny RL, Tosun D, Donohue MC, Aisen PS, Jagust WJ, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2016 May 17;86(20):1887-96. doi: 10.1212/WNL.0000000000002683. Epub 2016 Apr 15.

24.

Continuous Popliteal Sciatic Blocks: Does Varying Perineural Catheter Location Relative to the Sciatic Bifurcation Influence Block Effects? A Dual-Center, Randomized, Subject-Masked, Controlled Clinical Trial.

Monahan AM, Madison SJ, Loland VJ, Sztain JF, Bishop ML, Sandhu NS, Bellars RH, Khatibi B, Schwartz AK, Ahmed SS, Donohue MC, Nomura ST, Wen CH, Ilfeld BM.

Anesth Analg. 2016 May;122(5):1689-95. doi: 10.1213/ANE.0000000000001211.

25.

The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome.

Rafii MS, Wishnek H, Brewer JB, Donohue MC, Ness S, Mobley WC, Aisen PS, Rissman RA.

Front Behav Neurosci. 2015 Sep 14;9:239. doi: 10.3389/fnbeh.2015.00239. eCollection 2015.

26.

Differential Effects of Meal Challenges on Cognition, Metabolism, and Biomarkers for Apolipoprotein E ɛ4 Carriers and Adults with Mild Cognitive Impairment.

Hanson AJ, Bayer JL, Baker LD, Cholerton B, VanFossen B, Trittschuh E, Rissman RA, Donohue MC, Moghadam SH, Plymate SR, Craft S.

J Alzheimers Dis. 2015;48(1):205-18. doi: 10.3233/JAD-150273.

PMID:
26401941
27.

Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014.

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Cedarbaum J, Donohue MC, Green RC, Harvey D, Jack CR Jr, Jagust W, Morris JC, Petersen RC, Saykin AJ, Shaw L, Thompson PM, Toga AW, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2015 Jul;11(7):865-84. doi: 10.1016/j.jalz.2015.04.005. Review.

28.

The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding.

Beckett LA, Donohue MC, Wang C, Aisen P, Harvey DJ, Saito N; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2015 Jul;11(7):823-31. doi: 10.1016/j.jalz.2015.05.004. Review.

29.

Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease.

Insel PS, Mattsson N, Mackin RS, Kornak J, Nosheny R, Tosun-Turgut D, Donohue MC, Aisen PS, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Ann Clin Transl Neurol. 2015 May;2(5):534-47. doi: 10.1002/acn3.192. Epub 2015 Mar 21.

30.

Clinical trial management of participant recruitment, enrollment, engagement, and retention in the SMART study using a Marketing and Information Technology (MARKIT) model.

Gupta A, Calfas KJ, Marshall SJ, Robinson TN, Rock CL, Huang JS, Epstein-Corbin M, Servetas C, Donohue MC, Norman GJ, Raab F, Merchant G, Fowler JH, Griswold WG, Fogg BJ, Patrick K.

Contemp Clin Trials. 2015 May;42:185-95. doi: 10.1016/j.cct.2015.04.002. Epub 2015 Apr 10.

31.

Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument.

Amariglio RE, Donohue MC, Marshall GA, Rentz DM, Salmon DP, Ferris SH, Karantzoulis S, Aisen PS, Sperling RA; Alzheimer’s Disease Cooperative Study.

JAMA Neurol. 2015 Apr;72(4):446-54. doi: 10.1001/jamaneurol.2014.3375. Erratum in: JAMA Neurol. 2015 May;72(5):608.

32.

Impact of CRFR1 Ablation on Amyloid-β Production and Accumulation in a Mouse Model of Alzheimer's Disease.

Campbell SN, Zhang C, Roe AD, Lee N, Lao KU, Monte L, Donohue MC, Rissman RA.

J Alzheimers Dis. 2015;45(4):1175-84. doi: 10.3233/JAD-142844.

33.

The transitional association between β-amyloid pathology and regional brain atrophy.

Insel PS, Mattsson N, Donohue MC, Mackin RS, Aisen PS, Jack CR Jr, Shaw LM, Trojanowski JQ, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2015 Oct;11(10):1171-9. doi: 10.1016/j.jalz.2014.11.002. Epub 2014 Dec 9.

34.

Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials.

Donohue MC, Moghadam SH, Roe AD, Sun CK, Edland SD, Thomas RG, Petersen RC, Sano M, Galasko D, Aisen PS, Rissman RA.

Alzheimers Dement. 2015 Sep;11(9):1069-79. doi: 10.1016/j.jalz.2014.07.156. Epub 2014 Oct 7.

35.

A randomized, triple-masked, active-controlled investigation of the relative effects of dose, concentration, and infusion rate for continuous popliteal-sciatic nerve blocks in volunteers.

Madison SJ, Monahan AM, Agarwal RR, Furnish TJ, Mascha EJ, Xu Z, Donohue MC, Morgan AC, Ilfeld BM.

Br J Anaesth. 2015 Jan;114(1):121-9. doi: 10.1093/bja/aeu333. Epub 2014 Sep 23.

36.

The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.

Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, Weiner M, Aisen PS; Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Ageing; Alzheimer’s Disease Neuroimaging Initiative; Alzheimer’s Disease Cooperative Study.

JAMA Neurol. 2014 Aug;71(8):961-70. doi: 10.1001/jamaneurol.2014.803.

37.

Emerging β-amyloid pathology and accelerated cortical atrophy.

Mattsson N, Insel PS, Nosheny R, Tosun D, Trojanowski JQ, Shaw LM, Jack CR Jr, Donohue MC, Weiner MW; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Neurol. 2014 Jun;71(6):725-34. doi: 10.1001/jamaneurol.2014.446.

38.

Estimating long-term multivariate progression from short-term data.

Donohue MC, Jacqmin-Gadda H, Le Goff M, Thomas RG, Raman R, Gamst AC, Beckett LA, Jack CR Jr, Weiner MW, Dartigues JF, Aisen PS; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2014 Oct;10(5 Suppl):S400-10. doi: 10.1016/j.jalz.2013.10.003. Epub 2014 Mar 20.

39.

Barriers impeding serologic screening for celiac disease in clinically high-prevalence populations.

Barbero EM, McNally SL, Donohue MC, Kagnoff MF.

BMC Gastroenterol. 2014 Mar 5;14:42. doi: 10.1186/1471-230X-14-42.

40.

Design and implementation of a randomized controlled social and mobile weight loss trial for young adults (project SMART).

Patrick K, Marshall SJ, Davila EP, Kolodziejczyk JK, Fowler JH, Calfas KJ, Huang JS, Rock CL, Griswold WG, Gupta A, Merchant G, Norman GJ, Raab F, Donohue MC, Fogg BJ, Robinson TN.

Contemp Clin Trials. 2014 Jan;37(1):10-8. doi: 10.1016/j.cct.2013.11.001. Epub 2013 Nov 9.

41.

Liposomal bupivacaine as a single-injection peripheral nerve block: a dose-response study.

Ilfeld BM, Malhotra N, Furnish TJ, Donohue MC, Madison SJ.

Anesth Analg. 2013 Nov;117(5):1248-56. doi: 10.1213/ANE.0b013e31829cc6ae.

42.

Ultrasound-guided root/trunk (interscalene) block for hand and forearm anesthesia.

Madison SJ, Humsi J, Loland VJ, Suresh PJ, Sandhu NS, Bishop MJ, Donohue MC, Nie D, Ferguson EJ, Morgan AC, Ilfeld BM.

Reg Anesth Pain Med. 2013 May-Jun;38(3):226-32. doi: 10.1097/AAP.0b013e3182890d50.

43.

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.

Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ.

Lancet Neurol. 2013 Feb;12(2):207-16. doi: 10.1016/S1474-4422(12)70291-0.

44.

Conditional Akaike information under generalized linear and proportional hazards mixed models.

Donohue MC, Overholser R, Xu R, Vaida F.

Biometrika. 2011 Sep;98(3):685-700. Epub 2011 Jul 13.

45.

Continuous femoral nerve blocks: the impact of catheter tip location relative to the femoral nerve (anterior versus posterior) on quadriceps weakness and cutaneous sensory block.

Ilfeld BM, Loland VJ, Sandhu NS, Suresh PJ, Bishop MJ, Donohue MC, Ferguson EJ, Madison SJ.

Anesth Analg. 2012 Sep;115(3):721-7. doi: 10.1213/ANE.0b013e318261f326. Epub 2012 Jun 28.

46.

Impact of surgically induced weight loss on pelvic floor disorders.

Whitcomb EL, Horgan S, Donohue MC, Lukacz ES.

Int Urogynecol J. 2012 Aug;23(8):1111-6. doi: 10.1007/s00192-012-1756-5. Epub 2012 Apr 12.

PMID:
22527554
47.

Mixed model of repeated measures versus slope models in Alzheimer's disease clinical trials.

Donohue MC, Aisen PS.

J Nutr Health Aging. 2012 Apr;16(4):360-4. Review.

PMID:
22499459
48.

Continuous femoral nerve blocks: decreasing local anesthetic concentration to minimize quadriceps femoris weakness.

Bauer M, Wang L, Onibonoje OK, Parrett C, Sessler DI, Mounir-Soliman L, Zaky S, Krebs V, Buller LT, Donohue MC, Stevens-Lapsley JE, Ilfeld BM.

Anesthesiology. 2012 Mar;116(3):665-72. doi: 10.1097/ALN.0b013e3182475c35.

49.

Can consumers trust web-based information about celiac disease? Accuracy, comprehensiveness, transparency, and readability of information on the internet.

McNally SL, Donohue MC, Newton KP, Ogletree SP, Conner KK, Ingegneri SE, Kagnoff MF.

Interact J Med Res. 2012 Apr 4;1(1):e1. doi: 10.2196/ijmr.2010.

50.

Predictors of response to an attention modification program in generalized social phobia.

Amir N, Taylor CT, Donohue MC.

J Consult Clin Psychol. 2011 Aug;79(4):533-41. doi: 10.1037/a0023808. Erratum in: J Consult Clin Psychol. 2013 Feb;81(1):112.

Supplemental Content

Loading ...
Support Center